Cargando…
New anti-tuberculosis drugs and regimens: 2015 update
Over 480 000 cases of multidrug-resistant (MDR) tuberculosis (TB) occur every year globally, 9% of them being affected by extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis. The treatment of MDR/XDR-TB is unfortunately long, toxic and expensive, and the success rate largely unsat...
Autores principales: | D'Ambrosio, Lia, Centis, Rosella, Sotgiu, Giovanni, Pontali, Emanuele, Spanevello, Antonio, Migliori, Giovanni Battista |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005131/ https://www.ncbi.nlm.nih.gov/pubmed/27730131 http://dx.doi.org/10.1183/23120541.00010-2015 |
Ejemplares similares
-
Recent developments in the diagnosis and management of tuberculosis
por: Sulis, Giorgia, et al.
Publicado: (2016) -
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017) -
Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Sotgiu, Giovanni, et al.
Publicado: (2016) -
Post-tuberculosis sequelae and their socioeconomic consequences: worth investigating
por: Sotgiu, Giovanni, et al.
Publicado: (2021) -
Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence
por: Migliori, Giovanni Battista, et al.
Publicado: (2021)